Hepatitis C Drugs; Help Ease Symptoms, and In Many Cases, They Can Cure Infection
Hepatitis C drugs are used to treat Hepatitis C, an infection caused by a virus that attacks the liver and leads to inflammation. Hepatitis C is a viral infection caused by the hepatitis C virus (HCV), sometimes leading to serious liver damage. Hep C is the most widespread blood-borne disease in the world, and it is mainly transferred by intravenous drug use. Today, most people become infected with the hepatitis C virus by sharing needles or other equipment used for the preparation of drugs and injecting drugs.
Hepatitis
C drugs can help ease symptoms, and in many cases, they can cure the infection.
Hepatitis C drugs include antiviral drugs, such as ribavirin, mavyret, votive,
epclusa, zepatier, harvoni, combination drugs, and direct-acting antivirals. In
some people, newer medicines can eradicate the virus. Harvoni is a prescription
medicine used to treat adults with chronic hepatitis C (Hep C) genotype 1, 4,
5, or 6 infections with or without cirrhosis (compensated). Hepatitis C, caused
by the hepatitis C virus, has become a global burden.
According
to the U.S. Department of Health and Human Services, millions of Americans from
all walks of life are living with viral hepatitis, and most don’t know they
have the virus. Around 2.4 million people are estimated to be living with
hepatitis C in the United States. The Food and Drug Administration (FDA) has
approved Sovaldi (sofosbuvir) and Harvoni (ledipasvir and sofosbuvir) to treat the hepatitis C virus (HCV) in children ages 12 to 17. Harvoni and Sovaldi have been
also approved to treat HCV in adults.
The
most common Hepatitis
C Drugs are direct-acting antivirals (DAAs). A typical treatment plan
combines two or more DAAs. These drugs are also combined with ribavirin or
interferons. However, direct-acting antivirals are more effective than older
treatments such as ribavirin and interferon. Sofosbuvir-based direct-acting
antiviral therapy has revolutionized the treatment of hepatitis C virus (HCV)
infection. Daclatasvir is also approved by FDA for the treatment of HCV
genotype 3 in conjunction with sofosbuvir.
Comments
Post a Comment